From Bench to Bedside: Multifunctional Nanoplatforms in the Fight Against Non-alcoholic Fatty Liver Disease
Introduction Non-alcoholic fatty liver disease (NAFLD) has become the most prevalent liver disease globally, affecting approximately 25% of the adult population.1 With the global obesity epidemic, the incidence of NAFLD has exhibited a significant upward …